Conclusion: Overall, eszopiclone and lemborexant had a favorable profile, but eszopiclone might cause substantial adverse events and safety data on lemborexant were inconclusive. Doxepin, seltorexant, and zaleplon were well tolerated, but data on efficacy and other important outcomes were scarce and do not allow firm conclusions. Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available. Melatonin, ramelteon, and non-licensed
Zopiclone side effects
Across 12 first-hand reports, people mentioned a side effect 8 times (about 67 per 100 reports). The most common: fatigue, sleepwalking, memory blackouts. User reports show what people notice — they can't tell you whether Zopiclone is safe for you.
Reported side effects
fatigue2
sleepwalking1
memory blackouts1
tolerance1
withdrawal1
bad taste1
dependence1
In their own words
“with zopiclone 6 hours is enough for me and I not only feel more refreshed, but also less restless and anxious.”
“people in my house would find me in the middle of the night sleep walking and eating everything”
Is Zopiclone safe? What the research covers
AResearch: Strong41 meta-analyses · 145 randomized trials on PubMed
Lancet · 2022
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysisFront Psychiatry · 2025
Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysisConclusion: Most drugs were positive associated with nervous system disorders and gastrointestinal disorders. Data on some drugs like flurazepam, nitrazepam, triazolam, and zaleplon in some outcomes were mainly based on limited study with rare event and thus was highly uncertain and do not allow firm conclusions.
Drugs · 2023
The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials